If confirmed, Johns Hopkins surgeon Martin Makary, M.D., would take the reins at the FDA as the agency undergoes cost-cutting measures from the Trump administration. More: In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
read moreAfter reviewing additional clinical data, England’s drug-price watchdog NICE has slapped down Eli Lilly’s Kisunla and Biogen and Eisai’s Leqembi for a second time, after both were approved by the U.K.’s MHRA. More: In UK, it's strike 2 for Alzheimer's
read moreBoth Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda. More: In patent clash over injectable Keytruda, Merck and Halozyme dig
read more
NICE convenes third committee meeting for additional appraisal consideration More: Leqembi enters second consultation period following NICE draft guidance update Source: News
read more
Octapharma supports NHS in building resilient supply chain More: NHS patients receive UK-donated plasma medicines for first time in 30 years Source: News
read moreModerna sued Pfizer and BioNTech over three patents protecting its COVID-19 work back in 2022. Now, a U.S. administrative body has ruled that two of those patents are invalid. More: Pfizer, BioNTech notch US win—and loss in Germany—amid high-stakes patent
read more© 1994 - 2025 B.M. Pharmaceuticals